• *** This stock is shown as delisted in our database. *** If you think this isn't correct then please let us know
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of medical therapies to treat serious diseases in the United States.
Market Cap | 13.513 Billion | Shares Outstanding | 165.929 Million | Avg 30-day Volume | 5.076 Million |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | |
Price to Revenue | 9.6829 | Debt to Equity | 0.0418 | EBITDA | -247.206 Million |
Price to Book Value | 18.635 | Operating Margin | -25.0394 | Enterprise Value | 9.617 Billion |
Current Ratio | 4.323 | EPS Growth | -1.641 | Quick Ratio | 2.335 |
1 Yr BETA | 0.9549 | 52-week High/Low | 0.0 / | Profit Margin | -17.2421 |
Operating Cash Flow Growth | 31.8113 | Altman Z-Score | 5.5645 | Free Cash Flow to Firm | -181.282 Million |
Please sign in first
none
none
none
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
No longer subject to file | 2016-09-28 | 0 | |
|
No longer subject to file | 2016-09-28 | 0 | |
|
No longer subject to file | 2016-09-28 | 0 | |
POWELL ANDREW KENNETH WILLIAM SVP, GENERAL COUNSEL & CRP SEC |
|
No longer subject to file | 2016-09-28 | 0 |
HUNG DAVID PRESIDENT AND CEO |
|
No longer subject to file | 2016-09-28 | 0 |
|
No longer subject to file | 2016-09-28 | 0 | |
|
No longer subject to file | 2016-09-28 | 0 | |
|
No longer subject to file | 2016-09-28 | 0 | |
YANG TSELI LILY VP, FINANCE AND ACCOUNTING |
|
No longer subject to file | 2016-09-28 | 0 |
HIRMAND MOHAMMAD INTERIM CHIEF MEDICAL OFFICER |
|
No longer subject to file | 2016-09-28 | 0 |
|
No longer subject to file | 2016-09-28 | 0 | |
MCCOURT MARION CHIEF OPERATING OFFICER |
|
No longer subject to file | 2016-09-28 | 0 |
JARRETT JENNIFER CHIEF FINANCIAL OFFICER |
|
No longer subject to file | 2016-09-28 | 0 |
BIERLY RICK CFO (FORMER) |
|
28,744 | 2016-05-05 | 0 |
LOBACKI JOSEPH M CHIEF COMMERCIAL OFFICER |
|
19,365 | 2016-01-04 | 0 |
TEMPLEMAN THOMAS SVP, PHARMACEUTICAL OPERATIONS |
|
22,720 | 2015-09-29 | 0 |
RHODES JENNIFER J GC & CORPORATE SECRETARY |
|
11,090 | 2015-03-16 | 0 |
SEELY LYNN CHIEF MEDICAL OFFICER |
|
0 | 2015-02-17 | 0 |
|
5,807 | 2014-06-27 | 0 | |
KELSEY STEPHEN MICHAEL SVP OF NEW PROJECTS |
|
0 | 2014-02-18 | 0 |
COHEN CHERYL CHIEF COMMERCIAL OFFICER |
|
0 | 2014-02-18 | 0 |
|
691,101 | 2012-10-30 | 0 | |
|
No longer subject to file | 2011-06-07 | 0 | |
PALEKAR ROHAN CHIEF COMMERCIAL OFFICER |
|
16,666 | 2011-04-20 | 0 |
PROTTER ANDREW A VP, PRECLINICAL DEVELOPMENT |
|
0 | 2008-10-31 | 0 |
CHAKRAVARTY SARVAJIT VP OF MEDICINAL CHEMISTRY |
|
0 | 2008-10-31 | 0 |
HARBINGER CAPITAL PARTNERS MASTER FUND I, LTD. HARBINGER CAPITAL PARTNERS OFFSHORE MANAGER, L.L.C. HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS FUND, L.P. HARBINGER CAPITAL PARTNERS SPECIAL SITUATIONS GP, LLC HMC - NEW YORK, INC. |
|
No longer subject to file | 2008-10-03 | 0 |
HARBINGER CAPITAL PARTNERS MASTER FUND I, LTD. |
|
3,159,000 | 2008-08-01 | 0 |
|
2,995,000 | 2007-12-05 | 0 | |
|
2,689,664 | 2007-10-11 | 0 | |
|
0 | 2006-05-16 | 0 | |
|
992,873 | 2005-12-31 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
No current insider transactions |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|
Holder | Issuer | Net Short Position | Position Date | Origin |
---|